---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037124"
form_type: "8-K"
ticker: "DRMA"
cik: "0001853816"
company_name: "Dermata Therapeutics, Inc."
filed_at: "2026-08-11T20:06:20+00:00"
generated_at: "2026-08-11T20:08:39.537597+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dermata to launch Tome Foundational Treatment on Aug 25, 2026; cash $4.4M

## Summary
- Tome Foundational Treatment launch expected Aug 25, 2026; manufacturing and packaging complete.
- Cash and equivalents $4.4M at June 30, 2026 vs $7.5M at Dec 31, 2025; sufficient into Q4 2026.
- Q2 2026 R&D expenses $0.2M (down from $0.6M); SG&A $2.8M (up from $1.2M) on legal, marketing, compensation.
- Second DTC product, an OTC acne treatment, planned after Foundational Treatment launch.
- Company attended Be+Well Beauty and Wellness Show in June; began Tome social media campaign.

## SEC filing metadata
- accession: 0001493152-26-037124
- form_type: 8-K
- ticker: DRMA
- cik: 0001853816
- company_name: Dermata Therapeutics, Inc.
- filed_at: 2026-08-11T20:06:20+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1853816/000149315226037124/0001493152-26-037124-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1853816/000149315226037124/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037124
- JSON: https://secwatch.observer/filing/0001493152-26-037124.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037124.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.